Revolution Medicines CFO Jack Anders sells $6.7 million in stock

Chief Financial Officer of Revolution Medicines, Jack Anders, sold 35,750 shares of the company's stock on November 11, 2026, generating roughly $6.7 million in proceeds. The sale occurred at prices between $181.04 and $192.84 per share. The recent drop in stock price by 10.4% over the past week, although the stock has still seen a significant 168% increase over the past year, is worth noting.

Analysts, according to InvestingPro, currently view the stock as undervalued. In the past month, 18 analysts revised their earnings expectations upwards. Mr. Anders' sales were made under a pre-set 10b5-1 trading plan, which he established on August 12, 2026. Prior to these sales, Anders acquired the same number of shares through stock option exercises on the same date, costing him approximately $1.04 million.

The options were fully vested. Following these transactions, Mr. Anders now owns 119,216 shares of Revolution Medicines, including 43,650 restricted stock units. On the company's earnings front, Revolution Medicines reported a strong third quarter of 2026, with $197.6 million in net product sales, marking their first profitable quarter following the U.S. launch of their product, RASONQUE.

Despite a net loss of $407.5 million due to increased commercialization and late-stage development costs, RASONQUE's revenue has garnered investor interest. Stifel has reiterated its Buy rating for Revolution Medicines, with a price target of $230, suggesting the stock could be a buying opportunity if it falls below $200 per share.